Document is current

Article History

Received: 9 July 2024

Accepted: 22 November 2024

First Online: 4 February 2025

Declarations

:

: The study was conducted according to the International Council for Harmonisation guidelines and the Declaration of Helsinki. The trial protocol was approved by independent ethics committees and institutional review boards. Written informed consent was provided by patients ahead of study screening.

: Not applicable.

: FVdB has received speaker and/or consulting fees from AbbVie, Amgen, Galapagos, Janssen, Lilly, Merck, Novartis, Pfizer, and UCB Pharma. AD has received grant/research support from AbbVie, BMS, Celgene, Lilly, MoonLake, Novartis, Pfizer, and UCB Pharma; and honoraria or consultation fees from AbbVie, BMS, Janssen, Lilly, Novartis, Pfizer, and UCB Pharma. DP has received research support from AbbVie, Lilly, MSD, Novartis, and Pfizer; and consulting fees, speaking fees, and/or honoraria from AbbVie, Biocad, BMS, Galapagos, Gilead, GSK, Janssen, Lilly, MSD, Medscape, MoonLake, Novartis, Peervoice, Pfizer, Roche, Samsung Bioepis, and UCB Pharma. WPM has received grant/research support from AbbVie, Novartis, Pfizer, and UCB Pharma; consulting fees, speaking fees, and/or honoraria fees from AbbVie, BMS, Celgene, Galapagos, Gilead, Janssen, Lilly, Medscape, Novartis, Peervoice, Pfizer, and UCB Pharma; is Chief Medical Officer of CARE Arthritis Limited; and has received royalties or licenses from Augurex for the 14-3-3eta diagnostic biomarker. DvdH has received consulting fees from AbbVie, ArgenX, BMS, Galapagos, GSK, Janssen, Lilly, Novartis, Pfizer, Takeda, and UCB Pharma; and is an editorial board member of the Journal of Rheumatology, an editorial board member of RMD Open, an associate editor for the Annals of Rheumatic Diseases, an advisor for the Assessment of Axial Spondyloarthritis International Society, and the Director of Imaging Rheumatology BV. T-HK has received speaker fees from AbbVie, Celltrion, Kirin, Lilly, and Novartis. MK has received consulting fees and/or honoraria from AbbVie, Amgen, Asahi-Kasei Pharma, Astellas, Ayumi Pharma, BMS, Chugai, Daiichi Sankyo, Eisai, Gilead, Janssen, Lilly, Novartis, Ono Pharma, Pfizer, Tanabe-Mitsubishi, and UCB Pharma. XeB has received grant/research support from AbbVie and Novartis; consulting fees from AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, and UCB Pharma; speakers’ bureau fees from AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, and UCB Pharma; is an editorial board member of the Annals of Rheumatic Diseases; is the ASAS President; and is the EULAR President-elect. XiB, IL-G, I-HS, PW, KK, and AS are employees of AbbVie and may own stock or options.